Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/jcm10030512
Keywords
endoglin; microvessel density; rhabdomyosarcoma; soft tissue sarcoma; neoangiogenesis
Categories
Funding
- Maria Sklodowska-Curie National Research Institute of Oncology
Ask authors/readers for more resources
CD105 was found to be a relevant angiogenesis marker in pediatric RMS, with MVD/CD105 serving as an independent risk factor for short overall survival in children with RMS.
(1) Background: The study proposed to analyze microvessel density (MVD) in rhabdomyosarcoma (RMS) based on the expression of angiogenesis markers and define its prognostic role in this group of patients. (2) Methods: The study included forty-nine pediatric patients diagnosed with RMS. Tumor tissue expression of CD31, CD34, and CD105 was analyzed. MVD was calculated and correlated with clinical RMS prognostic parameters. (3) Results: CD31, CD34, and CD105 are expressed in all RMS cases. MVD/CD105 was significantly higher in the RMS group than in the control group. The mean and median values of MVD/CD105 in RMS were lower than MVD/CD31 and MVD/CD34. MVD/CD105 was significantly higher in patients with alveolar RMS and those with metastatic disease. Patients with higher levels of MVD/CD105 had a higher risk of death (HR = 1.009). (4) Conclusion: CD105 is a relevant angiogenesis marker in pediatric RMS, and MVD/CD105 is an independent risk factor of short overall survival in children with RMS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available